1-4 of 4
Vincent Sandanayaka
Close
Sort by
Journal Articles

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Rosa Lapalombella, Qingxiang Sun, Katie Williams, Larissa Tangeman, Shruti Jha, Yiming Zhong, Virginia Goettl, Emilia Mahoney, Caroline Berglund, Sneha Gupta, Alicia Farmer, Rajeswaran Mani, Amy J. Johnson, David Lucas, Xiaokui Mo, Dirk Daelemans, Vincent Sandanayaka, Sharon Shechter, Dilara McCauley, Sharon Shacham, Michael Kauffman, Yuh Min Chook, John C. Byrd
Journal: Blood
Blood (2012) 120 (23): 4621–4634.
https://doi.org/10.1182/blood-2012-05-429506
Published: 2012
Includes: Supplemental data
Journal Articles

Significant in Vivo Efficacy of the SINE KPT-330 in Mouse Models of CLL.

Rosa Lapalombella, PhD, Virginia Goettl, Katie Williams, Larissa Tangeman, Shruti Jha, Jason A Dubovsky, Ph.D, Danielle L Chappell, Amy J Johnson, PhD, Vincent Sandanayaka, Sharon Shechter, Dilara McCauley, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, John C. Byrd, MD
Journal: Blood
Blood (2012) 120 (21): 2452.
https://doi.org/10.1182/blood.V120.21.2452.2452
Published: 2012
Journal Articles

CRM1/XPO1 Represents a Promising Therapeutic Target for Treatment of Chronic Lymphocytic Leukemia

Rosa Lapalombella, PhD, Caroline Berglund, Emilia Mahoney, MD, PhD, Katie Williams, Shruti Jha, Asha Ramanunni, MD, Vincent Sandanayaka, Sharon Shechter, Dilara McCauley, Sharon Shacham, PhD, Michael Kauffman, MD, Ph.D., John C. Byrd, MD
Journal: Blood
Blood (2011) 118 (21): 232.
https://doi.org/10.1182/blood.V118.21.232.232
Published: 2011
Journal Articles

Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies

Sharon Shacham, PhD, MBA, Joel G Turner, PhD, Raphael Nir, Giulio Draetta, Vincent Sandanayaka, Sharon Shechter, Michael Kauffman, Daniel Sullivan, MD
Journal: Blood
Blood (2010) 116 (21): 3012.
https://doi.org/10.1182/blood.V116.21.3012.3012
Published: 2010